131I-MIBG With Myeloablative Chemotherapy and Autologous Stem Cell Transplantation for the Treatment of High-risk Neuroblastoma

Evaluation of Benefit and Side Effects of 131I-MIBG in Combination With Myeloablative Chemotherapy and Autologous Peripheral Blood Stem Cell Transplantation for the Treatment of High-risk Neuroblastoma

This trial is studying how well iodine I 131 metaiodobenzylguanidine together with combination chemotherapy works in treating patients who are undergoing an autologous peripheral stem cell for high risk or relapsed neuroblastoma.

Inclusion Criteria:

• Histologically confirmed Neuroblastoma and/or demonstration of tumor cells in bone marrow with elevated urinary catecholamine metabolites
• High risk according COG (Children Oncology Group)OR Relapse OR Refractory
• As at least one I131-MIBG avid target lesion determined by diagnostic MIBG scan
• Glomerular filtration rate or creatinine clearance > 60 ml/min
• No tumor cell in Bone Marrow by routine morphology aspiration and biopsy before peripheral stem cell collection
• No active infection

Exclusion Criteria:

• Impaired renal function
• No avid I131-MIBG lesion
• Active infection